This Science News Wire page contains a press release issued by an organization and is provided to you "as is" with little or no review from Science X staff.

Gene therapy approaches to treating nephropathia epidemica researched by Kazan Federal University

October 10th, 2019 Natalia Doroshkevich, Yury Nurmeev
Gene therapy approaches to treating nephropathia epidemica researched by Kazan Federal University
Pathway analysis of serum analytes in functional CCR5 homozygous and functional CCR5/Δ32CCR5 heterozygous NE—Interstitial Fibroblasts in Pyelonephritis. Pathway analysis was done using the Pathway Studio MammalPlus (Elsevier) tool. Analytes which differ significantly between groups were used for enrichment analysis. Only pathways with p < 0.05 after correction for the multiple comparisons were selected. Blue color highlights analytes which were significantly lower in functional CCR5/Δ32CCR5 heterozygous NE. Credit: Kazan Federal University

This particular inquiry pertains to CCR5—a gene which has lately been on the focuses of research worldwide. In particular, CCR5 deletion was used in China to perform the first ever genetic editing on human embryos. It's also known that a CCR5-Δ32 mutation can make people immune to HIV.

In this publication, the Gene and Cell Technology Lab team of Kazan University analyzed the connection between CCR5 genotype and susceptibility to hemorrhagic fever with renal syndrome in Tatarstanis. The typing was performed through polymerase chain reaction; 98 afflicted and 592 healthy individuals were tested during four years.

Junior Research Associate Yekaterina Martynova explains, "Republic of Tatarstan is a region with natural hot spots of HFRS and relatively high prevalence of the disease.

"We found that patients with the CCR5 / CCR5 homozygous genotype had a longer oliguric phase and lower platelet count in the blood compared with patients with the heterozygous genotype. In the blood of such homozygotes, a higher level of metalloproteinases was also detected. In contrast, in patients who had a heterozygous genotype, that is, had a Δ32 mutation in the CCR5 gene, these clinical parameters were least pronounced. Our data indicate a greater likelihood of damage to intracellular structures and a higher level of activation of the innate immunity system in patients with a homozygous genotype compared to heterozygous patients, that is, those having a Δ32 mutation in the CCR5 gene."

The paper is a joint undertaking by Kazan Federal University, University of Nevada, Kazan State Medical University, Kazan State Medical Academy, Tatarstan Republican Clinical Infection Hospital, and University of Nottingham.

Funding is provided by Project 5-100, Russia.

More information:
Konstantin Kletenkov et al. Δccr5 Genotype Is Associated with Mild Form of Nephropathia Epidemica, Viruses (2019). DOI: 10.3390/v11070675

Provided by Kazan Federal University

Citation: Gene therapy approaches to treating nephropathia epidemica researched by Kazan Federal University (2019, October 10) retrieved 25 April 2024 from https://sciencex.com/wire-news/332150714/gene-therapy-approaches-to-treating-nephropathia-epidemica-resea.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
Back to list